Replies to post #330674 on Innovation Pharmaceuticals Inc (IPIX)

[Tamtam]

Great post once again

[TheDane]

A Brilicidin inhaler is a game changer but we can’t get there until we’re in human trials for Covid. At least not realistically. Without the Covid connection IPIX couldn’t do much of anything at this time and we’d likely suffer a slow dwindling away. I’m confident in saying, that Leo was able to get BrilAcidin into the RBL for testing against Covid, and the resulting RBL (third party!) confirmation of the potential for BrilAcidin to treat Covid and, perhaps, other viruses, saved the company. I’d love to hear the details of how he did this some day.

Leo’s strategy to develop BrilAcidin as a Platform drug could be the key to vast wealth for him and other shareholders. The only problem is it takes time. Getting this stock to proper valuation based on yesterday’s and other near term news will relieve pressure for the company and “true longs.” I won’t mind waiting a round a few more years with the stock in the upper single digits, say, ranging between $5 and $9.99999999. Oh, on NYSE or Naz, of course. If the next few months shows BrilAcidin helping Covid patients then $9.9999999 will be toast, at least for a while.

Go Leo!

[thefamilyman]

Sticky material...

[xoc]

Who is Warren Weston? He is listed as working as a consultant for Innovation Pharm on the preprint server article

[petemantx]

Per your reading of the pre-print it seems that the RBL is still actively conducting investigations across a broad range of coronaviruses. Does this give you a strong sense of belief that a sizable grant will be given to GMU to continue with their PAN-CORONA investigation efforts as they requested in conjunction with IPIX? Who is paying now for their current efforts? Could they have received some govt funds directly that didn't require some sort of PR that would have been required if such had been granted to IPIX?

Is developing B in a inhaler form to be that severe a problem or is it pretty easy in today's world of medicine to perfect such a delivery system?

There appears to be a LOT of work to do for Brilaciidin across a wide range of possible indications as a virus killer of the first degree. Do you agree that one RBL (GMU) should handle the entire program regarding Brilacidin in this regard so it makes it quite easy to prepare further peer review articles down the line or would it be considered to make GMU the head of a broad range of investigations but farm out some of the leg work to other RBLs that may not be as busy? Or do you believe all the RBLs are taxed to the max currently on other CV efforts?

Thanks for taking the time to consider and respond on the above subjects. Having expert medical posters is such a wonderful feature for any board since most of the rest of us are medical midgets.

[To infinity and beyond!]

Prophylaxis again mentioned, no surprise. Will they even do the IV trial? With or without Remdesivir? It is going to take a lot longer to develop an inhaler or a nasal spray or a mask than q4. If an IV trial fails what will become of B? IP sells it at auction having run out of money?

Lots of questions.

[cybermich]

Great post!

I wonder how well the pps would respond once we are in multiple human trials with the help of government grants.

in this case patience wins the race:)

[Wayne R]

IPIX and Dr DeGrado have stated Brilacidin may be an effective treatment against a number of viruses.

May be?

Are they not sure?

[loanranger]

"Additional formulation work is planned for the inhaled delivery of brilacidin for prophylactic use, toward controlling infection in the nasal passage and lungs by leveraging brilacidin’s ability to inhibit SARS-CoV-2 by disrupting viral integrity and impacting viral entry. Such development efforts, if successful, may enable brilacidin to emerge as a particularly effective and differentiated antiviral by preventing and/or decreasing early infectivity due to SARS-CoV-2"

https://static1.squarespace.com/static/5715352e20c647639137f992/t/5f9b5de065b30770ea051cfd/1604017708904/Brilacidin+COVID-19+Manuscript+and+Supplemental+Information+fv+10.30.20.pdf




"A nasal spray that blocks the absorption of the SARS-CoV-2 virus has completely protected ferrets it was tested on, according to a small study released on Thursday by an international team of scientists. The study, which was limited to animals and has not yet been peer-reviewed, was assessed by several health experts at the request of The New York Times."
"The work has been underway for months by scientists from Columbia University Medical Center in New York, Erasmus Medical Center in the Netherlands and Cornell University in Ithaca, N.Y., The study was funded by the National Institutes of Health and the Columbia University Medical Center."

https://www.nytimes.com/2020/11/05/health/coronavirus-ferrets-vaccine-spray.html?action=click&module=RelatedLinks&pgtype=Article